Follicular lymphoma grade IIIb, spleen
ICD-10 C82.47 is a billable code used to indicate a diagnosis of follicular lymphoma grade iiib, spleen.
Follicular lymphoma is a type of non-Hodgkin lymphoma characterized by the proliferation of follicle center (germinal center) B-cells. Grade IIIb indicates a high-grade variant of this lymphoma, where there is a predominance of large cells. When the spleen is involved, it can lead to splenomegaly and may present with systemic symptoms. Patients may experience B-symptoms, which include fever, night sweats, and weight loss. The diagnosis is typically confirmed through histopathological examination of lymph node or spleen biopsies, revealing the characteristic follicular architecture and the presence of large cells. Staging of follicular lymphoma is crucial for determining prognosis and treatment options, which may include watchful waiting, chemotherapy, immunotherapy, or stem cell transplantation, depending on the disease stage and patient health. The prognosis for patients with grade IIIb follicular lymphoma can vary, and treatment is often tailored to individual patient needs.
Comprehensive documentation of diagnosis, staging, treatment plans, and follow-up care.
Diagnosis and management of newly diagnosed patients, treatment response evaluations, and management of relapsed disease.
Ensure accurate documentation of histological findings and any associated symptoms to support coding.
Detailed pathology reports including histological grading and immunophenotyping.
Biopsy evaluations for suspected lymphomas and grading of lymphoid tissues.
Pathology reports must clearly indicate the grade and subtype of lymphoma for accurate coding.
Used when a biopsy is performed to confirm the diagnosis of follicular lymphoma.
Pathology report must include details of the histological findings.
Pathologists must ensure accurate grading and subtype identification.
Common treatments include chemotherapy, immunotherapy, and in some cases, stem cell transplantation. Treatment plans are individualized based on the patient's overall health and disease stage.
